DK0661990T3 - Fremgangsmåde til systemisk behandling af kataboliske tilstande og systemisk vævsbeskadigelse - Google Patents

Fremgangsmåde til systemisk behandling af kataboliske tilstande og systemisk vævsbeskadigelse

Info

Publication number
DK0661990T3
DK0661990T3 DK93920354T DK93920354T DK0661990T3 DK 0661990 T3 DK0661990 T3 DK 0661990T3 DK 93920354 T DK93920354 T DK 93920354T DK 93920354 T DK93920354 T DK 93920354T DK 0661990 T3 DK0661990 T3 DK 0661990T3
Authority
DK
Denmark
Prior art keywords
systemic
tissue damage
catabolic conditions
treatment
igfbp
Prior art date
Application number
DK93920354T
Other languages
Danish (da)
English (en)
Inventor
Andreas Sommer
Christopher A Maack
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/984,936 external-priority patent/US5407913A/en
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of DK0661990T3 publication Critical patent/DK0661990T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK93920354T 1992-08-26 1993-08-26 Fremgangsmåde til systemisk behandling af kataboliske tilstande og systemisk vævsbeskadigelse DK0661990T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93589092A 1992-08-26 1992-08-26
US07/984,936 US5407913A (en) 1992-12-03 1992-12-03 Method and composition for systemic treatment of tissue injury
PCT/US1993/008025 WO1994004030A1 (fr) 1992-08-26 1993-08-26 Procede de traitement systemique d'etats cataboliques et de lesions tissulaires systemiques

Publications (1)

Publication Number Publication Date
DK0661990T3 true DK0661990T3 (da) 2002-06-17

Family

ID=27130081

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93920354T DK0661990T3 (da) 1992-08-26 1993-08-26 Fremgangsmåde til systemisk behandling af kataboliske tilstande og systemisk vævsbeskadigelse

Country Status (9)

Country Link
EP (1) EP0661990B1 (fr)
JP (1) JPH08500827A (fr)
AT (1) ATE215835T1 (fr)
CA (1) CA2142455A1 (fr)
DE (1) DE69331802T2 (fr)
DK (1) DK0661990T3 (fr)
ES (1) ES2174852T3 (fr)
PT (1) PT661990E (fr)
WO (1) WO1994004030A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016723A2 (fr) * 1993-01-29 1994-08-04 Synergen, Inc. Composition de cicatrisation de plaies
JPH08509873A (ja) * 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
CA2195474A1 (fr) * 1994-07-20 1996-02-01 Cedo Martin Bagi Complexe igf/igfbp pour promouvoir la formation de tissu osseux et pour reguler le remodelage osseux
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
WO1997009998A2 (fr) * 1995-09-14 1997-03-20 Bristol-Myers Squibb Company Proteine de liaison 3 du facteur de croissance insulinoide (igf-bp3) dans le traitement de tumeurs liees a p53
PT871730E (pt) * 1995-10-11 2004-11-30 Chiron Corp Combinacao de pdgf, kgf, igf e igfbp para cicatrizacao de ferimentos
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6593290B1 (en) * 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
WO1998050428A1 (fr) * 1997-05-05 1998-11-12 Mayo Foundation For Medical Education And Research Traitement de l'osteoporose
GB2369572A (en) 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
EP4606428A3 (fr) * 2018-06-27 2025-11-05 Juvena Therapeutics, Inc. Polypeptides associés à l'héparine et leurs utilisations
CN108998463A (zh) * 2018-08-24 2018-12-14 苏州红冠庄国药股份有限公司 一种人源胰岛素生长因子-1（igf-1）复合物的制备工艺
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
WO2022271466A1 (fr) 2021-06-21 2022-12-29 Juvena Therapeutics, Inc. Polypeptides régénérateurs et leurs utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent

Also Published As

Publication number Publication date
EP0661990B1 (fr) 2002-04-10
DE69331802D1 (de) 2002-05-16
EP0661990A1 (fr) 1995-07-12
JPH08500827A (ja) 1996-01-30
ATE215835T1 (de) 2002-04-15
DE69331802T2 (de) 2002-11-07
WO1994004030A1 (fr) 1994-03-03
ES2174852T3 (es) 2002-11-16
CA2142455A1 (fr) 1994-03-03
PT661990E (pt) 2002-09-30
EP0661990A4 (fr) 1995-05-22

Similar Documents

Publication Publication Date Title
DK0661990T3 (da) Fremgangsmåde til systemisk behandling af kataboliske tilstande og systemisk vævsbeskadigelse
ZA89813B (en) Method for treating renal diseases
SE8703625D0 (sv) New medical use
ATE187646T1 (de) Verwendung von kupfer enthaltenden wirkstoffen zur beschleunigung der wundheilung
DK408089D0 (da) Proteiner
ES2001967A6 (es) Un metoo para producir una proteina a partir de un cultivo de celulas.
ATE186840T1 (de) Zusammensetzungen und methoden zur wundbehandlung
MD1558F2 (en) Method of prophylaxis of mammal acute renal insufficiency utilizing IGF-I insulin-like growth factor
CA2045594A1 (fr) Compositions immunogenes contre les peptides de la gastrine
ATE188383T1 (de) Mischungen zum schutz und regenierung von geweben
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
AU6853290A (en) Composition and method for the treatment of osteoporosis in mammals
NO971566L (no) Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF
DE69523747D1 (de) Die kombination des wachstumhormones und des insulinähnlichen wachstumsfaktors-i zur behandlung von kongestivem herzversagen
ATE226958T1 (de) Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
DE69310528D1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
DE69423506D1 (de) Methode zur behandlung von reproduktionserkrankungen
DE69721824D1 (de) Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen
GR1002610B (el) Θεραπευτικες συνθεσεις πληγων που περιεχουν παραγοντα αναπτυξης ινοβλαστων και ασκορβικον οξυ.
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
SE9002731D0 (sv) Product comprising growth factor
DE69433687D1 (de) Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
SU1115731A1 (ru) Способ лечени послеожогового отека лица
RU94042315A (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки